Format
Sort by

Send to

Choose Destination

Search results

Items: 19

1.

Radiosynthesis and micro-SPECT analysis of triazole-based RGD integrin ligands as non-peptide molecular imaging probes for angiogenesis.

Bianchini F, Fabbrizzi P, Menchi G, Raspanti S, Bottoncetti A, Passeri A, Andreucci E, Guarna A, Calorini L, Pupi A, Trabocchi A.

Bioorg Med Chem. 2015 Mar 1;23(5):1112-22. doi: 10.1016/j.bmc.2014.12.065. Epub 2015 Jan 13.

PMID:
25637121
2.

Therapeutic efficacy of a novel non-peptide αvβ3 integrin antagonist for pathological retinal angiogenesis in mice.

Li YJ, Li XH, Wang LF, Kuang X, Hang ZX, Deng Y, Du JR.

Exp Eye Res. 2014 Dec;129:119-26. doi: 10.1016/j.exer.2014.11.004. Epub 2014 Nov 8.

PMID:
25446322
3.

Multivalency of non-peptide integrin αVβ3 antagonist slows tumor growth.

Kim YS, Li F, Kong R, Bai Y, Li KC, Fan Y, O'Neill BE, Li Z.

Mol Pharm. 2013 Oct 7;10(10):3603-11. doi: 10.1021/mp400096z. Epub 2013 Sep 5.

PMID:
23961901
4.

VivoTag-S680–conjugated 3-aminomethyl αvβ3 antagonist derivative for fluorescence molecular tomography of tumors.

Shan L.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Jan 06 [updated 2010 May 19].

5.

Gadolinium diethylenetriamine pentaacetic acid-Arg-Gly-Asp peptidomimetic.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Jun 15 [updated 2008 Jul 18].

6.

131I-Labeled arginine-arginine-leucine (RRL)-containing cyclic peptide (YCGGRRLGGC) for imaging prostate carcinoma.

Shan L.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2010 Jan 06 [updated 2010 Feb 16].

7.

4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine fluorescein thiourea .

Cheng KT, Danthi N, Xie J.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Oct 09 [updated 2008 Jan 2].

8.

4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethyloxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOTA-111In)-neopenta-1-carbamyl)]-aminoethylsulfonylamino-β-alanine.

Cheng KT, Paik CH, Danthi N.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2007 Jul 09 [updated 2007 Dec 18].

9.

Anti-angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laser-induced choroidal neovascularization in mice.

Honda S, Nagai T, Negi A.

Graefes Arch Clin Exp Ophthalmol. 2009 Apr;247(4):515-22. doi: 10.1007/s00417-008-1010-5. Epub 2008 Dec 2.

PMID:
19048271
10.

Novel vascular lesions in mice given a non-peptide vitronectin receptor antagonist.

Rehm S, Thomas RA, Smith KS, Mirabile RC, Gales TL, Eustis SL, Boyce RW.

Toxicol Pathol. 2007 Dec;35(7):958-71.

11.

Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.

Benfatti F, Cardillo G, Fabbroni S, Galzerano P, Gentilucci L, Juris R, Tolomelli A, Baiula M, Spartà A, Spampinato S.

Bioorg Med Chem. 2007 Dec 1;15(23):7380-90. Epub 2007 Aug 22.

PMID:
17869121
12.

Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.

Maubant S, Saint-Dizier D, Boutillon M, Perron-Sierra F, Casara PJ, Hickman JA, Tucker GC, Van Obberghen-Schilling E.

Blood. 2006 Nov 1;108(9):3035-44. Epub 2006 Jul 11.

13.

Synthesis, in vitro, and in vivo characterization of an integrin alpha(v)beta(3)-targeted molecular probe for optical imaging of tumor.

Burnett CA, Xie J, Quijano J, Shen Z, Hunter F, Bur M, Li KC, Danthi SN.

Bioorg Med Chem. 2005 Jun 1;13(11):3763-71.

PMID:
15863003
14.

Endothelin-B receptor blockade inhibits molecular effectors of melanoma cell progression.

Rosanò L, Spinella F, Genovesi G, Di Castro V, Natali PG, Bagnato A.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S136-9.

PMID:
15838263
15.

Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: effects of alphavbeta3 and alphaIIbbeta3 antagonists.

Gomes N, Vassy J, Lebos C, Arbeille B, Legrand C, Fauvel-Lafeve F.

Clin Exp Metastasis. 2004;21(6):553-61.

PMID:
15679053
16.

Non-peptide alpha v beta 3 antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives.

Wang J, Breslin MJ, Coleman PJ, Duggan ME, Hunt CA, Hutchinson JH, Leu CT, Rodan SB, Rodan GA, Duong LT, Hartman GD.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):1049-52.

PMID:
15013021
17.

Non-peptide alphavbeta3 antagonists. Part 6: design and synthesis of alphavbeta3 antagonists containing a pyridone or pyrazinone central scaffold.

Breslin MJ, Duggan ME, Halczenko W, Fernandez-Metzler C, Hunt CA, Leu CT, Merkle KM, Naylor-Olsen AM, Prueksaritanont T, Stump G, Wallace A, Rodan SB, Hutchinson JH.

Bioorg Med Chem Lett. 2003 May 19;13(10):1809-12.

PMID:
12729670
18.

Non-peptide alpha(v)beta(3) antagonists. Part 4: potent and orally bioavailable chain-shortened RGD mimetics.

Coleman PJ, Askew BC, Hutchinson JH, Whitman DB, Perkins JJ, Hartman GD, Rodan GA, Leu CT, Prueksaritanont T, Fernandez-Metzler C, Merkle KM, Lynch R, Lynch JJ, Rodan SB, Duggan ME.

Bioorg Med Chem Lett. 2002 Sep 2;12(17):2463-5.

PMID:
12161158
19.

Effects of the novel alphav integrin antagonist SM256 and cis-platinum on growth of murine squamous cell carcinoma PAM LY8.

Van Waes C, Enamorado-Ayala I, Hecht D, Sulica L, Chen Z, Batt DG, Mousa S.

Int J Oncol. 2000 Jun;16(6):1189-95.

PMID:
10811994
Items per page

Supplemental Content

Loading ...
Write to the Help Desk